
Exporters seek assistance, credit at affordable rates to deal with Trump tariff
In a meeting with Commerce and Industry Minister Piyush Goyal in Mumbai, certain exporters sought plans on the lines of the production-linked incentive (PLI) scheme, they added.
"Exporters share issues, which they may face in the American market because of the high duty announced by US President Donald Trump," one of the officials said, adding that the minister has suggested that the exporting community send their suggestions in writing.They also demanded loans at affordable rates and fiscal incentives.In India, according to exporters, interest rates range between 8 and 12 per cent or even more, depending on the spread and risk assessment of the borrower by authorised dealer banks. In competing countries, the interest rate is very low. For instance, the central bank rate is 3.1 per cent in China, 3 per cent in Malaysia, 2 per cent in Thailand, and 4.5 per cent in Vietnam.
The situation for sectors like apparel and shrimp is not good. US buyers have started cancelling orders or are holding back orders. In the coming months, it can impact India's exports to the US, and because of a dip in shipments, there could be job losses," they said, adding that it will be difficult for the government to extend fiscal incentives.The 25 per cent duty, announced this week, will come into force from August 7 (9.30 am IST). These will be over and above the existing standard import duty in the US.The sectors, which would bear the brunt of this high tax, include textiles/ clothing (10.3 billion), gems and jewellery (12 billion), shrimp (USD 2.24 billion), leather and footwear (USD 1.18 billion), chemicals (2.34 billion), and electrical and mechanical machinery (about USD 9 billion).The US accounts for over 30 per cent of India's leather and apparel exports.According to think tank GTRI, quick estimates suggest that India's goods exports in FY 2026 may come down by 30 per cent from USD 86.5 billion in the last fiscal to USD 60.6 billion in 2025-26.Sudhir Sekhri, Chairman, AEPC (Apparel Export Promotion Council), last week requested immediate government intervention to offset this huge setback."Exporters have their back against the wall and will have to sell below cost to keep their factories running and avoid mass layoffs," he has said.Plastic exporter from Delhi NCR region Arvind Goenka said that exports to the US will face stiff competition from competing countries as tariffs on India are one of the highest."The USA has fixed substantially lower tariffs on countries like Vietnam (20 per cent), Thailand (19 per cent) and South Korea (15 per cent), all of which excel in plastic goods production, and they may encroach into India's share, which currently is USD 2.2 billion annually," Goenka said.
India's leading footwear exporter and Farida Group Chairman Rafeeq Ahmed said the government should come forward to help the industry before a trade pact is finalised between India and the US.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
&w=3840&q=100)

Business Standard
a few seconds ago
- Business Standard
Britannia Q1 profit misses estimates, sees early signs of urban recovery
Britannia Industries posted first-quarter profit below estimates on Tuesday, but the Indian biscuit maker said urban consumption - dull for a few quarters - is picking up. The seller of 'Marie Gold' and 'Bourbon' biscuits joins other domestic consumer goods makers such as Hindustan Unilever and ITC in forecasting early signs of a recovery in urban demand, aided by easing local inflation. India's annual retail inflation slowed every month in the quarter, easing to a six-year low in June at 2.1 per cent. That helped spur a "marginal uptick in consumption across both urban and rural markets," said Varun Berry, managing director and chief executive. Britannia's quarterly sales grew 9.8 per cent to ₹4,535 crore ($516.5 million). The firm had previously flagged rise in popular demand for packaged food and confectionery items such as croissants, wafers and flavoured shakes - usually more likely to be bought on impulse. But total spends rose 10.4 per cent, led by a 15 per cent jump in raw material costs. Britannia has been hiking prices to partly offset the higher costs of raw materials such as cocoa, flour and palm oil. Profits in the reported quarter came in at ₹521 crore, up 3 per cent on-year, but below analysts' average estimate of ₹570 crore rupees, according to data compiled by LSEG.
&w=3840&q=100)

Business Standard
a few seconds ago
- Business Standard
Eris Lifesciences to tap Rs 5,000-cr insulin and semaglutide market in FY26
Ahmedabad-based Eris Lifesciences is looking to tap opportunities in the nearly Rs 5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced the withdrawal of its insulin products from the market in April this year. 'We expect that Novo's cartridge inventory in the market will run out by October 2025. So this market opportunity is something that one can start monetising from the November–December time frame,' the company's executive director and chief executive officer (CEO), Krishnakumar Vaidyanathan, told Business Standard. He added that the timing fits Eris' plans, as the cartridge filling capability of its Bhopal unit will start becoming operational from January. Vial manufacturing has already been commissioned at the unit, with the company creating a strategic stock of insulins. This comes at a time when Eris is already the largest domestic player in insulins. The company had acquired the India formulations business of Biocon Biologics last year — including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined Rs 60 crore in revenue last year. Basalog and Insugen had combined revenues of Rs 200 crore at the time of acquisition,' he said. He added that, with this, the company's insulin franchise has become significantly larger, with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of the blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of 2025–26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to-market strategy is concerned, the company said it is already in a strong position because of its dominant presence in insulins and prior presence in the GLP market with the launch of liraglutide in September last year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to Rs 125 crore. Revenue rose to Rs 773 crore during the June quarter against Rs 720 crore in the year-ago period.
&w=3840&q=100)

Business Standard
a few seconds ago
- Business Standard
P B Balaji, a CFO who plays with a straight bat, now captains JLR
Balaji's rise to the top spot at JLR as its CEO comes at a time when the company is in a transition phase, lining up plans for more electric vehicles Shine Jacob Chennai Listen to This Article His career moves across the world — from countries like Switzerland and Singapore to cities like London — meant his daughter had to switch nine schools in just 15 years. This is just one glimpse into the lesser-known personal side of the otherwise career-oriented Pathamadai Balachandran Balaji, who was elevated as the first Indian chief executive officer of Tata Motors-owned luxury carmaker Jaguar Land Rover (JLR) on Monday. However, his life is about more than just boardroom talks and business growth. Balaji, in his mid-50s, is a die-hard cricket enthusiast and an admirer of Virat Kohli, yet chooses not to